This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
== History == The forerunner of the present-day company was called Kyowa Hakko Kogyo Co., Ltd (協和醱酵工業株式会社, lit. 'Coordinated Fermentation Industry Share Company') and was established on July 1, 1949. The company merged with Kirin Pharma Co., Ltd., on October 1, 2008 to form Kyowa Hakko Kirin (KHK) with plans to spin off the bio-chemical business into Kyowa Hakko Bio. On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million. In 2019, Kirin Holdings acquired 95% stake in Kyowa Hakko Bio which is Kyowa Kirin's subsidiary corporation. The entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd. In November 2022, Kyowa Kirin announced plans to spin its International Established Medicines portfolio, consisting of 13 brands, into a new joint venture with German company Grünenthal. The joint venture would expand Grüenthal's already extensive pain management portfolio, while Kyowa Kirin saw it as a financial benefit and an opportunity to expand the brands. In October 2023, Kyowa Kirin acquired a Britain-based biopharmaceutical company, Orchard Therapeutics, for $478 million, aiming to expand their portfolio.
=== Progestogens === Progestins (progesterone-like drugs) such as megestrol acetate and medroxyprogesterone acetate have been used for the treatment of hormone-responsive, advanced breast cancer, endometrial cancer, and prostate cancer. Progestins are also used in the treatment of endometrial hyperplasia, a precursor to endometrial adenocarcinoma. The exact mechanism of action of these hormones is unclear, and may involve both direct effect on the tumor cells (suppression of estrogen receptor levels, alteration of hormone metabolism, direct cytotoxicity) and indirect endocrine effects (suppression of adrenal androgen production and plasma estrone sulfate formation).
Physicists were more accepting of Hahn's work, and he began attending a colloquium at the Physics Institute conducted by Heinrich Rubens. It was at one of these colloquia where, on 28 September 1907, he made the acquaintance of the Austrian physicist Lise Meitner. Almost the same age as himself, she was only the second woman to receive a doctorate from the University of Vienna, and had already published two papers on radioactivity. Rubens suggested her as a possible collaborator. So began the thirty-year collaboration and lifelong close friendship between the two scientists. In Montreal, Hahn had worked with physicists including at least one woman, Harriet Brooks, but it was difficult for Meitner at first. Women were not yet admitted to universities in Prussia. Meitner was allowed to work in the wood shop, which had its own external entrance, but could not enter the rest of the institute, including Hahn's laboratory space upstairs. If she wanted to go to the toilet, she had to use one at the restaurant down the street. The following year, women were admitted to universities, and Fischer lifted the restrictions and had women's toilets installed in the building.
NAD+ + ubiquinol This enzyme is a flavoprotein (FAD). It belongs to the family of oxidoreductases, specifically those acting on NADH or NADPH with other acceptors. The systematic name of this enzyme class is NADH:(quinone-acceptor) oxidoreductase. Other names in common use include reduced nicotinamide adenine dinucleotide (quinone) dehydrogenase, NADH-quinone oxidoreductase, NADH ubiquinone oxidoreductase, DPNH-menadione reductase, D-diaphorase, and NADH2 dehydrogenase (quinone), and mitochondrial (mt) complex I. This enzyme participates in oxidative phosphorylation. Several compounds are known to inhibit this enzyme, including AMP, and 2,4-dinitrophenol. NADH dehydrogenase is involved in the first step of the electron transport chain of oxidative phosphorylation (OXPHOS). Any change in the electron transport component caused by a mutation might effect the normal electron flow. This might be leading "an increase of bifurcation and generation of superoxidase radicals and increase oxidative stress in various types of cancer cells."
Urocanase (also known as imidazolonepropionate hydrolase or urocanate hydratase) is the enzyme (EC 4.2.1.49) that catalyzes the second step in the degradation of histidine, the hydration of urocanic acid to imidazol-4-one-5-propionic acid. Urocanase is coded for by the UROC1 gene, located on the third chromosome in humans. The protein itself is composed of 676 amino acids which then fold, producing the final product which has two identical subunits, making the enzyme a homodimer. To catalyze the hydrolysis of urocanate in the catabolic pathway of L-histidine the enzyme utilizes its two nicotinamide adenine dinucleotide (NAD+) groups. These act as electrophiles, attaching to the top carbon of the urocanate which leads to sigmatropic rearrangement of the urocanate molecule. This rearrangement allows for the addition of a water molecule, converting the urocanic acid into imidazol-4-one-5-propionic acid.
Sources: en.wikipedia.org
== Design == The design of an RTG is simple by the standards of nuclear technology: the main component is a sturdy container of a radioactive material (the fuel). Thermocouples are placed in the walls of the container, with the outer end of each thermocouple connected to a heat sink. Radioactive decay of the fuel produces heat. It is the temperature difference between the fuel and the heat sink that allows the thermocouples to generate electricity. A thermocouple is a thermoelectric device that can convert thermal energy directly into electrical energy using the Seebeck effect. It is made of two kinds of metal or semiconductor material. If they are connected to each other in a closed loop and the two junctions are at different temperatures, an electric current will flow in the loop. Typically a large number of thermocouples are connected in series to generate a higher voltage. RTGs and fission reactors use very different nuclear reactions. Nuclear power reactors (including the miniaturized ones used in space) perform controlled nuclear fission in a chain reaction. The rate of the reaction can be controlled with neutron absorbing control rods, so power can be varied with demand or shut off (almost) entirely for maintenance. However, care is needed to avoid uncontrolled operation at dangerously high power levels, or even nuclear accident. Chain reactions do not occur in RTGs. Heat is produced through spontaneous radioactive decay at a non-adjustable and steadily decreasing rate that depends only on the amount of fuel isotope and its half-life.
=== Metalorganic addition === Interaction of ethylene oxide with organomagnesium compounds, which are Grignard reagents, can be regarded as nucleophilic substitution influenced by carbanion organometallic compounds. The final product of the reaction is a primary alcohol:
== Precursor == Pepsin is expressed as a zymogen called pepsinogen, whose primary structure has an additional 44 amino acids compared to the active enzyme. In the stomach, gastric chief cells release pepsinogen. This zymogen is activated by hydrochloric acid (HCl), which is released from parietal cells in the stomach lining. The hormone gastrin and the vagus nerve trigger the release of both pepsinogen and HCl from the stomach lining when food is ingested. Hydrochloric acid creates an acidic environment, which allows pepsinogen to unfold and cleave itself in an autocatalytic fashion, thereby generating pepsin (the active form). Pepsin cleaves the 44 amino acids from pepsinogen to create more pepsin. Pepsinogens are mainly grouped in 5 different groups based on their primary structure: pepsinogen A (also called pepsinogen I), pepsinogen B, progastricsin (also called pepsinogen II and pepsinogen C), prochymosin (also called prorennin) and pepsinogen F (also called pregnancy-associated glycoprotein).
Potassium is a soft silvery solid that is easily cut with a knife. Because of the sensitivity of potassium to water and air, air-free techniques are normally employed for handling the element. It is unreactive toward nitrogen and saturated hydrocarbons such as mineral oil or kerosene. It readily dissolves in liquid ammonia, up to 480 g per 1000 g of ammonia at 0 °C to form the electride [K(NH3)6]+e−, which features an electron as an anion.
Delta hexatoxin Hv1 (δ-HXTX-Hv1a, Versutoxin, or Versutotoxin, formerly known as Delta atracotoxin Hv1 and δ-ACTX-Hv1a) is a neurotoxic component found in the venom of the Australian funnel web spider (Atrax robustus). Delta hexatoxin Hv1 can result in fatality for primates, by downregulating the inactivation of voltage gated sodium ion channels (VGSCs) found in motor neurons. The structure of versutoxin contains a central beta region with a cystine knot motif, commonly found in other neurotoxic polypeptides, but not found in sea anemone or alpha-scorpion toxins despite their similar effects in terms of sodium channel modulation.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.